WASHINGTON — A House committee plans to mark up next month legislation that would restrict U.S. biotechnology companies from doing business with a Chinese company that makes key drug ingredients, according to five lobbyists tracking the BIOSECURE Act. The goal is for the House to pass the bill before the July 4 recess, setting it up to be included in a year-end must-pass legislative package.
The BIOSECURE Act was written by leaders of the Select Committee on the Chinese Communist Party, in response to fears that Chinese biotechnology companies could threaten U.S. national security if they give the Chinese government access to sensitive health information about Americans.
The Select Committee is an ad-hoc panel created to build bipartisan consensus on China policies, but it does not have the authority to pass the bill. It’s up to the House Oversight and Accountability Committee, which is a permanent committee, to pass the BIOSECURE Act. The committee did not respond to questions about the markup.
Click this link for the original source of this article.
Author: John Wilkerson
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.